However, two should follow immediately. 😜 Yes, the goal is actually to reduce stocks and not add any new ones. But these two simply fit perfectly into my growth strategy, namely $WALMEX* (-0,37%) & $MELI (-4,31%) In addition, -6 + 2 still makes -4, which is a WIN WIN situation.

-------------------------------------------------------------------------------------------------

But unfortunately I can't get into the 2 stocks. With $MELI (-4,31%) I want to wait, as it is very highly valued and I see a certain downside potential in the next few weeks. With $WALMEX* (-0,37%) I have a limit order at €2.59, but I can't get in. Although the price has already fallen below it yesterday and today. The problem is that Trade Republic has a spread of 18-24 cents per Walmex share, i.e. almost 10% 😨

-------------------------------------------------------------------------------------------------

65Posizioni

18,49%

8

4 Commenti

GHF@GHF

4Mes

Maybe you should change brokers. At flatex, the spread at $WALMEX* is 6.7 %
But with such exotic securities you always have a higher spread, depending on the exchange.

•

1

•

Kate💎 🙌.

@Iwanowitsch

4Mes·

Good evening everyone,

The first steps have been taken. I sold the following shares today:

$KMB (+1,37%) A weak underperformer that operates in a business sector with a poor stomach.

I simply don't see any significant growth opportunities here over the next few years. I'd rather put the money into my broadly diversified world ETF or other investments. I got out with just under +10 %.

$PAYX (-0,77%) Out with around 6.5 % and the reasons for the sale are largely the same as for Kimberly-Clark.

$MSTR (-6,56%) After the rapid rise of the last few weeks, this has become too risky for me. I got out after a short holding period with around 28%.

In addition, the correlation with Bitcoin is very strong. And I'd rather hold my own $BTC (+0,88%) . From another perspective, if the value of the Bitcoin held is roughly half the market capitalization and you ignore the high level of debt, I still don't know where the other half of the market capitalization comes from.

The dividend aristocrat Procter & Gamble was actually also on the hit list for today $PG (+2,23%) Ecolab $ECL (-0,59%) and Colgate $CL (+2,47%) . I'm still not 100% sure about these, hence the vote. I would like to take a closer look. I was particularly fascinated by the 12m chart for Colgate. It looks as if a child has drawn a straight line from bottom left to top right. It's similar with Ecolab, where they have made around 45% in twelve months with dividends. (With Colgate around 40 %)

What happens next? The portfolio will be further reduced/concentrated. The BDCs are high on the hit list $ARCC (+0,18%)
$MAIN (-0,54%)
$HTGC (-0,77%)

REITs, on the other hand, can stay, as they currently have strong momentum and could benefit from falling interest rates. The only one I'm not quite sure about yet and would like to take a closer look at fundamentally when the opportunity arises is $STAG (+0,45%)

Kate💎 🙌.

@Iwanowitsch

4Mes·

Hey everyone,

I'm currently facing the challenge of reducing my portfolio from 77 to a maximum of 30 shares in order to get a better overview and focus my strategy. But I'm not sure how best to proceed.

Should I:

Sell the stocks that have done badly as they are obviously not performing well?
Or should I rather sell the ones that have performed best in order to take profits before things go downhill?
Or simply sell the 40 smallest positions? But there are also many interesting stocks in there that might be worth expanding.
Or simply sell everything that is heavily weighted in the MSCI World and thus reduce the cluster risk?

Perhaps there is a better approach? What do you look for when reducing your positions? Diversification, dividend yield, or simply the size of the individual positions in relation to the overall portfolio? I look forward to your opinions and tips!

Thanks in advance!

77Posizioni

15,75%

7

3 Commenti

Thomas@UndNun

4Mes

Incidentally, selling positions that have only made a loss immediately or later (i.e. possibly waiting to see if they rise) is not in itself a loss. See 'loss carryforward'. At least for us small investors.
Every year you can offset losses from previous years against realized gains from the current year tax-free. Up to 20000 euros each year. But only within the same asset class. So shares with shares and ETFs with ETFs, but not one with the other.

This means that if, for example, you make a loss of 30,000 euros when you sell your shares, you can take profits of up to 20,000 euros from other shares tax-free this year and another 10,000 euros the following year.
The nice thing about this is that, according to the current legal situation, this loss carryforward continues from one year to the next. As long as the legal situation does not change, you can only start to offset your current losses against your later gains in 10 years' time.

You could therefore 'save' these shares and hope for better times. However, there is a good chance that it would be better to let the money 'work' somewhere else in the meantime.

However, there is one problem with this. Normally, your bank will do all the clearing automatically (you'll have to ask). But if you use a neobroker, there are differences. Brokers who are 'tax-simple' will also do this for you. Just like banks, they automatically pay your taxes on profits and should also handle loss carryforwards correctly.
However, if your broker is not 'tax-simple' then you should receive paperwork once a year that you have to keep yourself and settle with the tax office. You may also need / want to have a tax advisor for this.

To complicate things further:
With a tax advisor, you can do your tax return up to 3 years later. 'Savings foxes' might come up with the idea of not paying tax on their profits from this year until 3 years from now and hope to make a nice return on their currently untaxed profits for the next 3 years.

•

4

•

Kate💎 🙌.

@Iwanowitsch

4Mes·

I think I will sell the following titles:

These stocks are very heavily represented in the MSCI World. This reduces cluster risk and frees up capital for speculative growth stocks.

-----------------------------------------------------

The REITs remain for the time being as they have positive momentum and will benefit strongly from future interest rate cuts.

------------------------------------------------------

$MRK (+2,28%)

$PFIZER

$JNJ (+2,12%)

Flying out as I don't understand the industry well enough.

$HIMS (-26,15%) remains, on the other hand.

------------------------------------------------------

Defensive stocks are out, as no excess return is to be expected here.

--------------------------------------------------------

$AMD (-2,29%) and $INTC (-4,07%) These are my turnaround candidates, as soon as this is completed, they are out

--------------------------------------------------------

The following titles are also on the hit list:

-----------------------------------------------------------

What do the more experienced among you say? Are there any titles on my list that are worth keeping? Do you see any gross misjudgments? Do you have any suggestions for improvement?

Thanks in advance.

Kate💎 🙌.

@Iwanowitsch

4Mes·

Hey everyone,

I'm currently facing the challenge of reducing my portfolio from 77 to a maximum of 30 shares in order to get a better overview and focus my strategy. But I'm not sure how best to proceed.

Should I:

Sell the stocks that have done badly as they are obviously not performing well?
Or should I rather sell the ones that have performed best in order to take profits before things go downhill?
Or simply sell the 40 smallest positions? But there are also many interesting stocks in there that might be worth expanding.
Or simply sell everything that is heavily weighted in the MSCI World and thus reduce the cluster risk?

Perhaps there is a better approach? What do you look for when reducing your positions? Diversification, dividend yield, or simply the size of the individual positions in relation to the overall portfolio? I look forward to your opinions and tips!

Thanks in advance!

77Posizioni

15,75%

12

23 Commenti

Soprano@Soprano

4Mes

That doesn't make sense, no. If you are already investing in individual stocks, why are you throwing out the best ones to go into "speculative growth stocks"?
The same applies to the healthcare sector. If you don't understand the established players, in what constellation do you understand those that are difficult to assess anyway? Defensive stocks are out ... because they are defensive? And AMD is not a "turnaround candidate" - you simply bought far too expensively.

All in all, it gives the impression that you don't really understand individual stocks, i.e. which stocks to buy why and how to value the companies in the first place. I also don't know if you're interested in learning, otherwise you should probably just stick to ETFs (I'm very reluctant to recommend that).

But what it shouldn't be, at least, is that you look at individual stocks as something where you pick the ones that tell a nice story in the hope that you're going to beat the market big time.

•

11

•

Bardok

@AE23

8Mes·

New ATH

$ECL (-0,59%)

Still convinced of the investment 😁

4

6 Commenti

Epi@Epi

8Mes

How? You're convinced even though ecl made a new ATH? Wow!

•

1

•

Visualizza tutti 2 ulteriori risposte

Bardok

@AE23

1Anno·

$ECL (-0,59%)

Yay. Bill Gates shares @work again 🥹

Quarterly figures exceeded 😁

7

Felix

@Investor_in_Jogginghose

1Anno·

Ecolab $ECL (-0,59%) posted higher sales in the fourth quarter, lifted by increased prices and new business, especially in its institutional and specialty division.

The water, hygiene and infection-prevention services company had a fourth-quarter profit of $405.2 million, or $1.41 a share, up from $264.4 million, or 93 cents a share, in the same quarter a year earlier.

Stripping out one-time items, adjusted earnings were $1.55 a share. Analysts surveyed by FactSet expected $1.54 a share.

Sales rose 7% to $3.94 billion. Analysts expected $3.75 billion.

Constant-currency sales in its industrial business rose 3%, while the same figure rose 13% in the Institutional and Specialty division, lifted by higher prices and new business.

2

Ecolab

Price

Discussione su ECL

Good quarterly figures

Ecolab share analysis

Titoli di tendenza